09:40 AM EDT, 10/09/2025 (MT Newswires) -- GeneDx ( WGS ) said Thursday it is launching the Autism Partnership Program, which aims to provide actionable insights earlier in the diagnostic process by expanding access to its exome and genome testing.

Joining the program as the founding partner is Jaguar Gene Therapy, which will initiate a genetic testing program for people clinically suspected of having SHANK3-related autism spectrum disorder and Phelan-McDermid syndrome, GeneDx ( WGS ) said.

GeneDx ( WGS ) shares were 4.8% higher in recent trading.

Price: 123.80, Change: +1.11, Percent Change: +0.90